Biotechnology company developing therapies for Alzheimer's disease and other neurodegenerative disorders.
Cassava Sciences, Inc. is an innovative biotechnology company in the clinical stage, specializing in the development of novel treatments for neurodegenerative diseases. At the forefront of its research is simufilam, a promising small molecule drug that has successfully completed Phase 2b clinical trials. This therapeutic candidate is targeted towards addressing the complex challenges posed by neurodegenerative conditions.
In addition to its therapeutic endeavors, Cassava Sciences is advancing SavaDx, an investigational diagnostic product designed as a blood-based biomarker. SavaDx aims to revolutionize Alzheimer's disease detection by providing a reliable diagnostic tool, potentially offering earlier and more accurate diagnosis than current methods.
Originally incorporated as Pain Therapeutics, Inc., Cassava Sciences underwent a strategic rebranding in March 2019 to reflect its evolving focus and commitment to neurodegenerative research. Headquartered in Austin, Texas, the company leverages decades of scientific expertise and dedication to advance therapies that address significant unmet needs in neurological healthcare.
With a steadfast dedication to innovation and patient-centered care, Cassava Sciences continues to expand its scientific understanding and therapeutic capabilities in the pursuit of transformative treatments for neurodegenerative diseases.